[EN] NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES TRICYCLIQUES DU RÉCEPTEUR SENSIBLE AU CALCIUM
申请人:MERCK SHARP & DOHME
公开号:WO2015095261A1
公开(公告)日:2015-06-25
Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.
[EN] NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS<br/>[FR] NOUVEAUX ANTAGONISTES TRICYCLIQUES DU RÉCEPTEUR SENSIBLE AU CALCIUM POUR LE TRAITEMENT DE L'OSTÉOPOROSE
申请人:MERCK SHARP & DOHME
公开号:WO2015089842A1
公开(公告)日:2015-06-25
Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof:
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
[EN] THERAPEUTIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET MÉTHODES D'UTILISATION ASSOCIÉS
申请人:GENENTECH INC
公开号:WO2021097110A1
公开(公告)日:2021-05-20
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
[EN] HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE TEAD POUR LE TRAITEMENT DU CANCER
申请人:GENENTECH INC
公开号:WO2022020716A1
公开(公告)日:2022-01-27
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.